# 2026-07451: FDA Greenlights Generic Party for Addiction Treatment Drug REVIA

2026-07451, Determination That REVIA (Naltrexone Hydrochloride) Tablets, 50 Milligrams Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-04-16, effective 2026-04-16; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-07451
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-07451
- Title: Determination That REVIA (Naltrexone Hydrochloride) Tablets, 50 Milligrams Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 20471
- Published: 2026-04-16
- Effective: 2026-04-16
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Greenlights Generic Party for Addiction Treatment Drug REVIA

## Summary

The FDA has decided that REVIA (naltrexone hydrochloride) 50 mg tablets weren’t taken off the market because of safety or effectiveness problems. This means generic drug makers can keep getting approval to sell their versions of REVIA, helping patients access affordable options. No changes in safety rules or extra costs are expected, so things stay steady for doctors, patients, and pharmacies.

## Abstract

The Food and Drug Administration (FDA or Agency) has determined that REVIA (naltrexone hydrochloride) tablets, 50 milligrams (mg), was not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.

## Effects PRIA read

- Generic Approvals Can Continue: benefit, medium. On April 16, 2026, FDA determined that REVIA (naltrexone hydrochloride) 50 mg was not withdrawn from sale for reasons of safety or effectiveness. Because of that decision, FDA will continue to approve abbreviated new drug applications (ANDAs) that refer to REVIA as long as those ANDA applicants mee…
- Existing ANDA Approvals Preserved: benefit, low. FDA will not begin procedures to withdraw approval of any already-approved ANDAs that refer to REVIA (naltrexone hydrochloride) 50 mg. That means companies holding approved generic versions that reference REVIA keep their approvals in place rather than facing withdrawal procedures.
- REVIA Remains in Orange Book Discontinued List: mixed, low. FDA will continue to list REVIA (naltrexone hydrochloride) 50 mg in the Orange Book’s "Discontinued Drug Product List," showing it was discontinued for reasons other than safety or effectiveness. The listing reflects that the NDA (018932) was withdrawn at the request of the sponsor and does not sig…
- Possible Labeling Updates for Generics: benefit, low. FDA said that if it determines labeling for REVIA should be revised to meet current standards, the Agency will advise ANDA applicants to submit updated labeling. That means future generic applicants may be asked to use revised labeling to match current regulatory expectations.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-07451 on federalregister.gov](https://www.federalregister.gov/documents/2026/04/16/2026-07451/determination-that-revia-naltrexone-hydrochloride-tablets-50-milligrams-was-not-withdrawn-from-sale)
- [2026-07451 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-04-16/pdf/2026-07451.pdf)

## Related
- [Previous: 2026-07450, Issuance of Multiple Exemptions](https://policyrisk.com/federal-register/2026-07450)
- [Next: 2026-07452, Notice Announcing Teacher and School Leader Incentive Program Competition; Corr…](https://policyrisk.com/federal-register/2026-07452)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-07451 (as of 2026-06-08).
